Recently, it was reported that exogenous bone morphogenetic protein (BMP)-2 acted as an antiproliferative agent in a variety of cell lines, including normal and cancerous gastric cell lines, indicating that BMP-2 plays an important role during cell growth. However, despite the loss of BMP-2 expression in several cancers, the underlying mechanism remains unknown. Epigenetic silencing through DNA methylation is one of the key steps during carcinogenesis. In this study, we found, through analysis by the methylation-specific polymerase chain reaction technique, CpG island methylation of the BMP-2 promoter region in gastric and colon cancer cell lines. BMP-2 mRNA was found to be activated after 5-aza-2 0 -deoxycytidine treatment of the methylation-positive cells. Moreover, 24 of the 56 (42.9%) gastric cancer tissues exhibited promoter methylation. Immunohistochemical staining revealed that 18 of the 24 (75%) gastric cancer tissues without methylation signals exhibited BMP-2 expression, whereas among 20 cancer tissues with strong methylation signals only four (20%) expressed BMP-2 (P ¼ 0.0003). These findings indicate that BMP-2 methylation is strongly associated with the loss of BMP-2 protein expression in the primary gastric carcinomas. BMP-2 methylation was more often observed in diffuse type (60.7%) than in intestinal type (25%) gastric carcinomas (P ¼ 0.007). Thus, aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be related to gastric carcinogenesis, particularly in the diffuse type.
Introduction
Bone morphogenetic protein (BMP)-2 is a member of the BMP family belonging to the transforming growth factor b (TGF-b) superfamily (von Bubnoff and Cho, 2001) . BMPs exert their effects via specific type I (Ia/ ALK3 and Ib/ALK6) and type II serine-threonine kinase receptors (BMPR). Binding of BMP-2 to BMPRII induces oligomerization of the receptor complex, resulting in phosphorylation of BMPRI and recruitment of downstream signaling proteins (von Bubnoff and Cho, 2001 ).
BMP-2 was first described as a factor inducing bone and cartilage formation (Wozney et al., 1988; Hogan, 1996) . However, the BMP pathway was subsequently shown to be involved in cellular differentiation and organogenesis (von Bubnoff and Cho, 2001; Hardwick et al., 2004) . BMP-2 plays an important role during digestive organ development, including stomach gland formation (Narita et al., 2000) , and is highly expressed in the normal human stomach and colon (van den Brink et al., 2001; Hardwick et al., 2004) . Our previous study demonstrated that BMP-2 inhibited cell growth, and induced cell differentiation in normal and cancerous gastric cell lines (Wen et al., 2004) . BMP-2 inhibits cell proliferation and induces differentiation in colorectal cancer (CRC) cells as well (Hardwick et al., 2004) . Furthermore, BMP-2 expression is lost at an early stage in human familial adenomatous polyposis lesions (Hardwick et al., 2004) . Growth inhibition and loss of BMP-2 have been implicated in prostate cancer (Ide et al., 1997; Horvath et al., 2004) too, indicating the tumor suppressor activity of BMP-2. However, despite the loss of BMP-2 expression in several cancers, the underlying mechanism remains unknown.
DNA methylation of CpG islands in the promoter regions of many genes has been correlated with silencing of tumor suppressor genes (Baylin et al., 1998; Jones and Baylin, 2002; Smiraglia and Plass, 2002) . Genome scans for aberrant DNA methylation have shown that up to 10% of CpG islands are methylated in human malignancies (Costello et al., 2000) . Silencing of genes by DNA hypermethylation could be the sole mechanism of gene inactivation, or cooperate with genetic mechanisms to inactivate putative tumor suppressor genes in tumors. Recently, it was reported that BMP3B, a member of the BMP family, was methylated in non-small-cell lung cancer (Dai et al., 2004) .
In spite of growing evidence linking the loss of BMP-2 and downstream target functions to cancer development, mutation in this gene has not been reported. To clarify the role of BMP-2 in carcinogenesis, we assessed BMP-2 expression and methylation in gastrointestinal carcinoma cells.
Results

Expression of BMP-2 and BMP receptors in gastrointestinal cancer cell lines
To determine if the BMP-2 signaling pathway is intact, we investigated the mRNA expression of BMP-2, BMP-4 and their three receptors, BMPRIa, BMPRIb and BMPRII. RT-PCR analysis revealed that the mRNAs of BMP-4, BMPRIa and BMPRIb were found in all cell lines except one, and BMPRII mRNA was detected in all cell lines (Table 1) . Strikingly, compared with the relatively ubiquitous expression of BMP-4 and BMPR, loss of BMP-2 mRNA was frequently observed in gastric and colorectal cancer cell lines (Table 1 , and Figure 1a and c). BMP-2 and its receptors were expressed in the normal stomach (Table 1 and  Figure 1a) , which is consistent with other results obtained for mice and humans by RT-PCR analyses and immunohistochemical staining. In such studies, BMP-2 and all of the BMP receptors were found to be expressed in the normal gastrointestinal tract (van den Brink et al., 2001; Hardwick et al., 2004) .
Frequent epigenetic silencing of BMP-2 in gastric and colorectal cancer cell lines We used a demethylation agent, 5-aza-2 0 -deoxycytidine (DAC), to initially study the epigenetic status of BMP-2 in gastrointestinal cancer cell lines. The basally silent BMP-2 gene was re-expressed with this treatment in each cell line tested (Figure 1a and c). The silenced BMP-2 gene has the characteristics of a hypermethylated gene (Cameron et al., 1999a; Suzuki et al., 2002) , since treatment with a histone deacetylation inhibitor, trichostatin A (TSA), alone, failed to reactivate this gene, but it synergistically does so with a low dose of DAC (Figure 1b) . Moreover, BMP-2 expression was restored in HCT116 DKO cells (Figure 1c) , in which two key DNA methyltransferase genes, DNMT1 and DNMT3b, had been biallelically disrupted with resultant virtual abolition of DNA methyltransferase activity (Rhee et al., 2002) .
Aberrant CpG island methylation of the BMP2 promoter region in cultured and primary gastric and colorectal cancer cells We studied the promoter methylation status of BMP-2 by means of methylation-specific PCR (MSP) analysis. Figure 2 ) in four cell lines, and normal stomach and colon mucosae. PCR products recognizing unmethylated (lanes U) and methylated (lane Mt) CpG sites were analysed in 2.5% agarose gels. To the right, MSP analysis was performed on HCT116 and DKO cells.
Through identification of a new expressed sequence tag (EST) in a database search and published data (Helvering et al., 2000; Ghosh-Choudhury et al., 2001; Abrams et al., 2004) combined with a homology search, we have clarified the CpG islands associated with the BMP-2 5 0 promoter region (Figure 2 ). MSP analyses revealed this island to be typical in having an unmethylated status in the normal stomach and colon ( Figure 1d ). KATOIII and RKO cells, which do not basally express BMP-2, exhibited a methylation signal, MKN74, which expresses the gene, was partially methylated, and MKN45, which expresses the gene, had no signal for methylation ( Figure 1d ). The methylation analyses, thus, are consistent with the BMP-2 expression patterns in these cells. In addition, CRC HCT116 cells only contained signals for methylated alleles of BMP-2, whereas only unmethylated alleles were found in DKO cells ( Figure 1d ).
We further performed MSP analysis on primary tissue samples. Methylation of BMP-2 was seen in none of 10 normal stomach mucosae examined ( Figure 3c ) nor in four normal colon mucosae (data not shown). In contrast to the normal patterns, BMP-2 was frequently hypermethylated in primary gastric carcinomas, with strong MSP methylation signals in 24 of 56 (42.9%) gastric carcinomas (Figure 3) .
In representative samples, we verified the MSP results by bisulfite sequencing (Figure 4 ). BMP-2 expressionnegative cultured tumor cells (KATOIII and HCT116) and a methylation-positive primary gastric carcinoma sample (TG2) showed dense methylation of the promoter CpG island, but expression-positive cells (MKN45) and a normal stomach sample (TG2N) showed only scattered methylation within the examined regions.
BMP-2 expression on immunohistochemistry and its correlation with the BMP-2 methylation status
We investigated the expression of BMP-2 in normal and gastric cancer tissues by means of immunohistochemical staining. BMP-2 was highly expressed in the epithelial cytoplasm of the normal stomach and showed an increasing expression pattern from the pit to the gland, with the highest expression in the base of the gland (Figure 5a ), where chief cells, pepsinogen-secreting cells, are abundantly present. Our results are quite similar to the expression patterns obtained by another group (van den Brink et al., 2001) . BMP-2 was also expressed in the normal colon mucosae (data not shown). In contrast, BMP-2 expression was obviously decreased in many gastric carcinomas. Of the 44 gastric cancer cases examined, 22 (50%) had no or weak expression compared with the corresponding normal mucosae in the same sections (Table 2 ). We studied whether or not there is any correlation between the methylation statuses and BMP-2 expression. A representative cancer case, TG46, possessing unmethylated alleles of BMP-2, exhibited positive staining in the cytoplasm of the carcinoma cells (Figure 5b ), while methylated cancer cells (TG2) exhibited negative staining (Figure 5c ). Among the 20 primary gastric carcinoma samples with strong methylation signals on MSP, only four (20%) exhibited BMP-2 expression, whereas 18 of the 24 (75%) cases without methylation signals exhibited BMP-2 expression (Table 2 ). Fisher's exact probability test demonstrated a significant decrease in BMP-2 expression in strong methylation signal cases compared with that in unmethylated gastric carcinoma ones (P ¼ 0.0003).
The relationship between the methylation frequencies of BMP-2 and clinicopathological parameters The clinicopathological characteristics of the patients with the BMP-2 methylation status are shown in Table 3 . Methylation of the BMP-2 promoter was more frequently found in the diffuse type (17/28, 60.7%) than in the intestinal type (7/28, 25%) of gastric carcinomas (P ¼ 0.007) (Figure 3 and Table 3 ).
Effects of BMP-2 on cell proliferation and protein expression in OUMS-37 rat gastric cells We previously reported that BMP-2 inhibited the proliferation of OUMS-37 rat gastric cells (Wen et al., 2004) . We further analysed whether or not the BMP antagonist noggin can reverse the BMP-2 effect. Noggin directly binds to BMP-2 and prevents the interaction between BMP-2 and its receptors (Zimmerman et al., 1996) . As shown in Figure 6a , recombinant human (rh)BMP-2 induced inhibition of proliferation in OUMS-37 cells, while addition of purified noggin protein reversed the BMP-2 inhibition.
The inhibition of OUMS-37 cell proliferation in response to BMP-2 may be due to an increased level of p21/WAF1/CIP1, a cyclin-dependent kinase inhibitor (Wen et al., 2004) . We further investigated the protein level of the cell cycle inducer cyclin D1 by Western blotting assaying (Figure 6b ). rhBMP-2 decreased the cyclin D1 level in OUMS-37 cells (Figure 6b, lane 3) .
Since BMP-2 methylation was more often observed in diffuse type than intestinal type gastric cancers (Table 3) , we determined whether BMP-2 upregulates the protein level of E-cadherin, a calcium-dependent cell adhesion molecule. As shown in Figure 6b , OUMS-37 cells treated with rhBMP-2 expressed the increased E-cadherin protein level. 
Discussion
Aberrant methylation of CpG islands in promoter regions may lead to the transcriptional silencing of various genes in gastric cancer (Leung et al., 2001) . It has been reported that approximately 40% of gastric cancers exhibit the CpG island methylator phenotype (Toyota et al., 1999) . We found here that cultured gastric and CRC cells without BMP-2 expression exhibited methylation of the BMP-2 CpG island, while cells with high BMP-2 expression did not. In addition, treatment of cultured cells with demethylating agent DAC exhibited reactivated BMP-2 expression, and a low dose of DAC combined with TSA reactivated BMP-2 synergistically, despite the failure of the drug, alone, to activate the gene. DNA methylation is regulated by three DNA methyltransferases, DNMT1, DNMT3a and DNMT3b, and DNA methylation is reduced by greater than 95% globally in CRC cells that lack both DNMT1 and DNMT3b (DKO cells) (Rhee et al., 2002) . These changes result in restoration of p16INK4A, TIMP3, GATA4 and GATA5 (Rhee et al., 2002; Akiyama et al., 2003) , indicating that DNMT1 and DNMT3b play critical roles in the gene silencing associated with colon cancer. Consistent with these results, demethylation and restoration of BMP-2 expression were observed in DKO cells. Therefore, DNMT1 and/or DNMT3b are necessary for catalysis of methylation of the 5 0 CpG island of BMP-2. Thus, the loss of BMP-2 expression in the gastric and colorectal cancer cells may be strongly related to BMP-2 gene promoter methylation.
BMP-2 methylation was found in 24 of the 56 (42.9%) primary gastric carcinomas. The methylation frequency in cancers with negative or weak BMP-2 expression was significantly higher than that in ones with positive expression, and all the normal tissues examined exhibited no BMP-2 methylation. Therefore, the BMP-2 gene may be silenced through methylation in primary gastric carcinomas as well as in cultured gastrointestinal cancer cells.
Several recent findings suggest the involvement of BMP signaling in the tumorigenesis of several organs including the gastrointestinal tract. First, the antiproliferative activity of rhBMP-2 in vitro has been implicated in several cancer cells, such as prostate, gastric and colon (Ide et al., 1997; Hardwick et al., 2004; Wen et al., 2004) . Second, loss of BMP-2 expression has been reported for several cancers, including prostate and colon (Hardwick et al., 2004; Horvath et al., 2004) . Third, mutations in BMPRIa and Smad4 are implicated in juvenile polyposis (Howe et al., 1998 (Howe et al., , 2001 , and these patients are at risk for developing gastrointestinal cancers. Thus, any molecular alterations in the BMP signaling cascade may contribute to tumorigenesis. Epigenetic silencing of BMP-2 would result in a reduction of BMP signaling, linking the loss of function of this gene to tumor formation in the gastrointestinal tract.
BMP-2 was abundantly expressed in normal stomach epithelia and exhibited an increasing expression pattern from the pit to the gland region, with the highest expression in the base of the gland, where chief cells, which secrete pepsinogen and no longer proliferate, are located, supporting our previous finding that recombinant human BMP-2 upregulated the expression of pepsinogen II in cultured gastric cells (Wen et al., 2004) . BMP-2 also acts on mature epithelial cells in the colon (Hardwick et al., 2004) . These data, combined with the findings for antiproliferation effects of BMP-2 in gastric and CRC cells (Hardwick et al., 2004; Wen et al., 2004) , suggest that the loss of BMP-2 signaling may prevent cells from differentiating into mature cells and cause them to continually divide, leading to gastric and colorectal cancers.
Inhibition of the cell growth of breast cancer cells and aortic smooth muscle cells by BMP-2 is thought to be mediated by p21/WAF1/CIP1, a cyclin-dependent kinase inhibitor (Ghosh-Choudhury et al., 2000; Pouliot and Labrie, 2002; Wong et al., 2003) . We also reported that BMP-2 upregulated the p21 protein level in OUMS-37 rat gastric cells (Wen et al., 2004) . In this report, the protein level of the cell cycle inducer cyclin D1 decreased with BMP-2 treatment in OUMS-37 cells. Decreases in the cyclin D1 and cyclin-dependent kinase 2 levels were also seen in BMP-4-treated human fetal lung fibroblasts (Jeffery et al., 2005) . These alterations may result in hypophosphorylation of the retinoblastoma (Rb) protein, leading to the inhibition of cell cycle progression (Ghosh-Choudhury et al., 2000; Miyazaki et al., 2004) .
BMP-2 methylation was more often observed in diffuse type than intestinal type gastric cancers. One of the characteristics of diffusely progressed gastric cancer is that the gland structure is completely destroyed. Ecadherin is a calcium-dependent cell adhesion molecule whose intact function is crucial for the establishment and maintenance of epithelial tissue polarity and structural integrity. It is generally known that defects in the E-cadherin gene, such as somatic mutations, loss and methylation, are associated with the development of diffuse type gastric carcinomas (Becker et al., 1994; Oda et al., 1994; Yoshiura et al., 1995) . Since treatment with BMP-2 induced an increase of the E-cadherin protein level in OUMS-37 rat gastric cells, as shown in Figure 6b and in human neonatal calvaria cells (Hay et al., 2000) , it is possible that loss of BMP-2 might also influence the E-cadherin level in gastric cells. Further analyses are necessary to clarify the mechanism underlying the BMP-2 action on gastric carcinogenesis in detail.
In conclusion, our study has provided evidence that BMP-2 may play important roles in modulating gastrointestinal epithelial cell behavior, and the defect of BMP-2 signaling secondary to epigenetic silencing of BMP-2 may contribute to gastrointestinal carcinogenesis. It is intriguing to speculate that restoration of BMP-2 expression could contribute to new therapeutic strategies for gastric carcinoma.
Materials and methods
Cell lines and tissue samples
We studied four human gastric cancer cell lines (MKN45, KATOIII, MKN74 and MKN7), two human CRC cell lines (RKO and HCT116), a rat gastric epithelial cell line (OUMS-37) (Pu et al., 1999) and 56 primary gastric carcinoma samples. All primary normal and neoplastic tissues studied were randomly obtained from an affiliated hospital of the School of Medicine, Tokyo Medical and Dental University, between October 1999 and March 2001. Informed consent was obtained from all subjects, and the study was approved by the institutional review committee. Resected tissues were fixed with 10% phosphate-buffered formalin, embedded in paraffin and cut into 4-mm-thick sections with a microtome. Histological classification of the gastric cancers was performed according to Lauren's classification and the general rules established by the Japanese Gastric Cancer Association (Lauren, 1965; Japanese Gastric Cancer Association, 1998) .
Cell culture
The gastric and colon cancer cell lines, and OUMS-37 cells were grown in Dulbecco's modified Eagle's, RPMI1640 or McCoy's medium supplemented with 10% fetal bovine serum, penicillin and streptomycin. For demethylation studies, cells were daily treated with 5 mM 5-aza-2 0 deoxycytidine (DAC; Sigma, St Louis, MS, USA) for 48 h (Suzuki et al., 2002) . We also treated KATOIII cells with 0.3 mM TSA (WAKO, Osaka, Japan) alone, and with a combination of 0.1 mM DAC and TSA (Cameron et al., 1999a; Suzuki et al., 2002) .
OUMS-37 cells were treated with 100 ng/ml of recombinant human (rh)BMP-2 (obtained from Astellas Pharma Inc., Japan) or the same volume of vehicle (LF6) (Wen et al., 2004) . To assess the effect of recombinant mouse noggin (R & D Systems, Inc., Abingdon, UK) on BMP-2, noggin (1 mg/ml) and rhBMP-2 (100 ng/ml) were preincubated for 1 h at 371C and then added to the OUMS-37 cells. Cell proliferation assays were conducted as described previously (Wen et al., 2004) using Cell Proliferation Reagent WST-1 (Roche Diagnostics, Mannheim, Germany) according to the protocol recommended by the manufacturer.
RT-PCR procedures
Total RNA was isolated with Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA). For RT-PCR, 2 mg of total RNA was reverse transcribed using a Superscript kit (Invitrogen). We amplified all genes with multiple cycle numbers (24-35 cycles) to determine semiquantitative differences in their expression levels. The product sizes and primer sequences were as follows: BMP-2 (GenBank Accession No. AL035668), 328 bp, 5 0 -CTA CATGCTAGACCTGTATCGC-3 0 (sense) and 5 0 -ATTTCG AGTTGGCTGTTGCAGG-3 0 (antisense); BMP-4 (GenBank Accession No. NM_001202), 326 bp, 5 0 -CCACAGCACTG GTCTTGAGTATCC-3 0 (sense) and 5 0 -TGTGGTGGACCA GTCTCGTGTCC-3 0 (antisense); BMPRIb (GenBank Accession No. NM_001203), 333 bp, 5 0 -ACTCGAGTTGGCAC CAAACGC-3 0 (sense) and 5 0 -ATGCAGGATTGTGAGCC CAGC-3 0 (antisense); the BMPRIa and BMPRII primer pairs were those previously described (Wen et al., 2004) . The PCR products were confirmed by sequencing.
Methylation analysis DNA extraction, bisulfite treatment, DNA sequencing and MSP were performed as described previously (Herman et al., 1996; Cameron et al., 1999b) . The primer sequences of BMP-2 for the unmethylated reaction were 5 0 -GGATGGTTGTTTT GAGTTATGGGTTGT-3 0 (sense) and 5 0 -CCTTAAAAACCA ACACCCAAAAAACACA-3 0 (antisense), and for the methylated reaction 5 0 -GGTTGTTTCGAGTTATGGGTCGC-3 0 (sense) and 5 0 -AAAACCAACGCCCGAAAAACGCG-3 0 (antisense), according to the GenBank sequence (Accession No. AL035668). The primers for bisulfite sequencing of BMP-2 were 5 0 -TATTGTAGGAGATYGGGGGTTTGG-3 0 (sense) and 5 0 -TACTATCRTCCTCCTTAAAAACCAAC-3 0 (antisense).
Immunohistochemistry
Paraffin sections (4 mm) were dewaxed and rehydrated in xylene and ethanol. For antigen retrieval, the sections were autoclaved in 0.01 M citrate buffer (pH 6.0) for 30 min, followed by immersion in 3% H 2 O 2 methanol for 15 min to block endogenous peroxidase. The sections were then blocked in 15% normal donkey serum in phosphate-buffered saline, followed by incubation with polyclonal anti-BMP-2 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:50) overnight at 41C. Then, the sections were incubated with biotinylated donkey anti-goat IgG diluted at 1:100 in 15% normal donkey serum for 30 min at room temperature. The standard ABC process was then performed according to the instructions for a goat ABC Staining System (Santa Cruz Biotechnology). Diaminobenzidine was used as a chromogen, followed by counterstaining with hematoxylin. We regarded as BMP-2 expression-positive when 10% or more cancer cells exhibited BMP-2 in the cytoplasm.
Western blot analysis
Western blot analyses of the cyclin D1 and E-cadherin proteins were performed as described previously (Wen et al., 2004) . Monoclonal antibodies to the cyclin D1 (Novocastra Laboratories Ltd, Newcastle, UK) and E-cadherin (BD Pharmingen, San Diego, CA, USA) were diluted at 1:400 and 1:2500, respectively.
